Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.58 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL28416254 | 0.91 | ADORA2B (0.50) | ADORA2BCCR1CCR5CCR8MEN1 | |
| SCHEMBL1704888 | 0.89 | MEN1 (0.50) | ADORA2BCCR1CCR5CCR8MEN1 | |
| SCHEMBL901793 | 0.78 | ADORA2B (0.55) | ADORA2BADORA2AADORA1MAPT | |
| SCHEMBL901187 | 0.77 | KARS1 (0.53) | — | |
| SCHEMBL18039107 | 0.76 | ADORA2B (0.68) | ADORA2BMEN1KMT2AADORA2AADORA1 | |
| SCHEMBL842949 | 0.74 | CCR1 (0.67) | CCR1CCR5CCR8MEN1KMT2A | |
| SCHEMBL19020245 | 0.73 | CCR1 (0.59) | CCR1CCR5CCR8MEN1KMT2A | |
| SCHEMBL12657557 | 0.72 | CCR1 (0.64) | CCR1CCR5CCR8MEN1KMT2A | |
| SCHEMBL1704539 | 0.71 | ADORA2B (0.51) | ADORA2BADORA2AMAPT | |
| SCHEMBL27960673 | 0.70 | CCR1 (0.46) | CCR1CCR5CCR8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-04-09 | — | — | US | claimed |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-02-08 | — | — | US | claimed |
| EP-3262034-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | Palobiofarma, S.L. (ES) | 2018-01-03 | — | — | EP | claimed |
| WO-2016135048-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2016-09-01 | — | — | WO | claimed |
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-04-09 | — | — | US | disclosed |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-02-08 | — | — | US | disclosed |
| EP-3262034-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | Palobiofarma, S.L. (ES) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135048-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | ADORA2B, MTNR1A, ADORA3 | ADORA2B 1/4885CCR1 4279/4885CCR5 2936/4885 |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | ADORA2B, MTNR1A, ADORA3 | ADORA2B 1/4885CCR1 4279/4885CCR5 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.